Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 May;47(5):1752-5.
doi: 10.1128/AAC.47.5.1752-1755.2003.

Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release

Elizabeth A Coyle  1 , Raymond Cha, Michael J Rybak
Affiliations

Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release

Elizabeth A Coyle et al. Antimicrob Agents Chemother. 2003 May.

Abstract

An in vitro model was used to compare the effects of linezolid, clindamycin, and penicillin, alone and in combination, on streptococcal pyrogenic exotoxin A (SPE A) release against virulent group A streptococci (GAS). All regimens exhibited lower (P < 0.05) SPE A release at 1 h than those with penicillin alone. Linezolid and clindamycin, alone or in combination with penicillin, may optimize the treatment of GAS infections by reducing bacterial burden and exotoxin release.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
In vitro pharmacodynamic activity of study antimicrobial regimens against S. pyogenes 166 (A) and 2616 (B). Since no statistically significant differences were observed between growth controls that were run at the three drug elimination rates, the growth curve for the fastest elimination rate (1 h) is depicted for each respective study isolate. GC, growth control (•); P, penicillin (○); C, clindamycin (▿); L, linezolid (▾); P/C, penicillin plus clindamycin (♦); P/L, penicillin plus linezolid (▪); L/C or C/L, linezolid plus clindamycin (□).
FIG. 2.
FIG. 2.
SPE A quantification (pg/ml) with S. pyogenes 166 (A) and 2616 (B). GC, growth control; P, penicillin; C, clindamycin; L, linezolid; P/C, penicillin plus clindamycin; P/L, penicillin plus linezolid; L/C, linezolid plus clindamycin. The lower limit of this assay was 1.4 pg/ml.
See this image and copyright information in PMC

References

    1. Blaser, J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A):125-130. - PubMed
    1. Cappelletty, D. M., and M. J. Rybak. 1996. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model. Antimicrob. Agents Chemother. 40:1148-1152. - PMC - PubMed
    1. Dresser, L. D., and M. J. Rybak. 1998. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18:456-462. - PubMed
    1. Gemmell, C. G., and M. McLeod. 1992. The effect of roxithromycin on the virulence of gram-positive cocci. Diagn. Microbiol. Infect. Dis. 15:67S-70S. - PubMed
    1. Gemmell, C. G., P. K. Peterson, D. Schmeling, Y. Kim, J. Mathews, L. Wannamaker, and P. G. Quie. 1981. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J. Clin. Investig. 67:1249-1256. - PMC - PubMed

Publication types

MeSH terms